TY  - BOOK
AU  - J. Rick Turner
AU  - Dilip R. Karnad
AU  - Snehal Kothari 
TI  - Cardiovascular Safety in Drug Development and Therapeutic Use: New Methodologies and Evolving Regulatory Landscapes 
SN  - 	3319403478
PY  - 2016///
CY  - Durham, North Carolina USA
PB  - Springer
KW  -  
N1  - Contents:

A Primer of Biological and Physiological Considerations

A Primer of Statistical Considerations

Proarrhythmic Cardiac Safety

Additional Domains of Cardiovascular Safety

Additional Considerations in General Drug Safety and Therapeutic Use

Afterword

Index

N2  - At a time when the field of cardiac safety is going through important changes, this unique book provides the rationale for, and cutting-edge explanations of, new regulatory landscapes that will likely govern cardiac safety assessments globally for the foreseeable future. Exposure-response modeling is already being accepted by regulatory agencies in lieu of the traditional Thorough QT/QTc Study, and the Comprehensive in vitro Proarrhythmia Assay initiative is well under way.

Developments in the field of cardiovascular safety are also described and discussed in the book. These include the search for more efficient ways to exonerate new drugs for type 2 diabetes from an unacceptable cardiovascular liability, how best to address off-target blood pressure increases induced by noncardiovascular drugs, and the continued evolution of the discipline of Cardio-oncology.


“a resource that will likely serve as a standard for years to come”

- Dr Jonathan Seltzer

Therapeutic Innovation & Regulatory Science, 2017;51(2):180



“I have no hesitation in recommending this book as a valuable reference source”

- Dr Rashmi Shah

Journal for Clinical Studies, 2017;9(1):62-63

; Common terms and phrases:

active additional addressed adverse events analysis approach appropriate approval assessment associated benefit blood pressure cancer cardiac cardiac safety cardiovascular safety cell changes channel chapter Clin clinical trials colleagues common compared concern conducted considerations considered determine discussed disease dose drug drug development drug-induced drug’s early effects efficacy employed estimate et al evaluation evidence example function given greater heart hERG human hypertension important increase individuals interest interval limit marketing mean measurement medicine meta-analysis monitoring multiple myocardial infarction noted occur outcome participants patients Pharmacol Phase possible potential practice presented proarrhythmic prolongation protein QT interval randomized reduced reference regulatory reporting response risk significant silico statistical structure term Ther therapeutic therapy tion treatment treatment group Turner type 2 diabetes values ventricular
ER  -